For Healthcare Professionals - International

CoreValve Evolut R OUS

TAVI System

Lowest Delivery Profile Across All Valve Sizes

14Fr-Equivalent System with InLineTM Sheath Improves Access1 and Reduces Risk of Major Vascular Complications2

Evolut R Video

Watch the Evolut R System


Evolut R CV-R Device

Now indicated for transarterial access vessel diameters ≥ 5.0mm.1

4Fr Reduction in Delivery Profile

Evolut R 14Fr EnVeo R Chart
Drawn to scale. Not actual French sizes.

Designed for 1st Time Positioning Accuracy

With 1:1 Response and Self-Centering

Evolut R First Time Positioning Accuracy

Option to Fully Recapture and Reposition*

Evolut R Fully Recapture Photo
* Up to ~80% deployment. Medtronic Data on File.

Exceptional Valve Performance and Reduced Significant PVL5

With Optimized Oversizing, Consistent Radial Force, and Extended Sealing Skirt*

Evolut R Exceptional Value Performance
  * Available on 26 and 29 mm valve sizes.
** Based on combined radial force curve for CoreValve 26, 29 and 31 mm transcatheter valves.

References:

  1. Medtronic, Inc. IFU M054712T001.
  2. Sheath to Femoral Artery Ratio (SFAR) greater than 1.05 predicted higher rates of VARC major vascular complications. Hayashida K, et al. Transfemoral aortic valve implantation. JACC Intv 2011;4(8):851-8.
  3. Genereux P, et al. Vascular complications after transcatheter aortic valve replacement: insights from the PARTNER (Placement of Aortic Transcatheter Valve) trial. JACC 2012;60(12):1043-52.
  4. Tchetche D, et al. Update on the need for a permanent pacemaker after transcatheter valve implantation using the CoreValve® AccuTrak™ system. EuroIntervention 2012 Sep; 8(5):556-62.
  5. Medtronic data on file, comparison of CoreValve to CoreValve Evolut/Evolut R. Significant PVL defined as ≥ moderate PVL.
  6. Popma J, et al. Transcatheter aortic valve replacement using a self-expanding bioprosthesis in patients with severe aortic stenosis at extreme risk for surgery. JACC 2014;63(19):1972-81.

Confidence. Delivered.